

14 April 2025

## ASX Announcement

### Change in Company Secretary

PolyNovo Limited announces that Mr. Lior Harel has resigned his employment with the Company to pursue other opportunities and will step down from the role of General Counsel and Company Secretary on 15 April 2025.

Lior has been a valuable member of the Company's senior leadership team and has led the Company's legal, company secretarial and regulatory affairs functions over the last year.

The PNV Board and management team thank Lior for his service and wish him the best in his future endeavours.

Mr. Jan-Marcel Gielen, the Company's Chief Financial Officer, will assume the responsibilities of Company Secretary for PolyNovo Limited until appointment of a replacement.

This announcement has been authorised by the Board of Directors of PolyNovo Limited.

#### About PolyNovo®

PolyNovo is a disruptive ASX medical technology company, headquartered in Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. After treating 70,000+ patients across 46 countries, the company is investing for growth via new products, indications, and markets. For more information see [polynovo.com](https://polynovo.com).

#### About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.